Efficacy of sodium thiosulfate for the treatment for calciphylaxis

Clinical Nephrology

Volumn 75, Issue 6, 2011, Pages 485-490

  Noureddine, L ^a   Landis, M ^a,b   Patel, N ^a   Moe, S M ^a,c  

^a INDIANA UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcific uremic arteriolopathy; Cutaneous; End stage renal disease

Indexed keywords

SODIUM THIOSULFATE; CHELATING AGENT; THIOSULFATE;

ADULT; AGED; ARTICLE; CALCINOSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MALE; MORTALITY; OBESITY; PERITONEAL DIALYSIS; PROGNOSIS; RARE DISEASE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SKIN DEFECT; MIDDLE AGED; NONPARAMETRIC TEST; PAIN ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; CALCIPHYLAXIS; CHELATING AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THIOSULFATES; TREATMENT OUTCOME;

EID: 79960958949     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75485     Document Type: Article

References (34)

1. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP. Cutaneous necrosis from calcific uremic arteriolopathy (see comments).AmJ Kidney Dis. 1998; 32: 384-391.
2. Fine A, Zacharias J. Calciphylaxis is usually nonulcerating: risk factors, outcome and therapy. Kidney Int. 2002; 61: 2210-2217.
3. Hafner J, Keusch G, Wahl C, Sauter B, Hurlimann A, von Weizsacker F, Krayenbuhl M, Biedermann K, Brunner U, Helfenstein U. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy (see comments). J Am Acad Dermatol. 1995; 33: 954-962.
4. Campistol JM, Almirall J, Martin E, Torras A, Revert L. Calcium-carbonate-induced calciphylaxis. Nephron. 1989; 51: 549-550.
5. Russell R, Brookshire MA, Zekonis M, Moe SM. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca × P product and aggressive wound care. Clin Nephrol. 2002; 58: 238-243.
6. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. Acase control study of proximal calciphylaxis [see comments].Am J Kidney Dis. 1998; 32: 376-383.
7. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. 2001; 37: 1267-1276.
8. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001; 60: 324-332.
9. Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG. Calciphylaxis in man.Asyndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976; 136: 1273-1280.
10. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003; 59: 463-470.
11. Rogers NM, Teubner DJ, Coates PT. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial. 2007; 20: 150-157.
12. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001; 21: 817-824.
13. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004; 43: 1104-1108.
14. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant. 2005; 20: 1260-1262.
15. Brucculeri M, Cheigh J, Bauer G, Serur D. Longterm intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial. 2005; 18: 431-434.
16. ArayaCE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol. 2006; 1: 1161-1166.
17. Hayden MR, Kolb LG, Khanna R. Calciphylaxis and the cardiometabolic syndrome. J Cardiometab Syndr. 2006; 1: 76-79.
18. Meissner M, Bauer R, Beier C, Betz C, Wolter M, Kaufmann R, Gille J. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology. 2006; 212: 373-376.
19. Tokashiki K, Ishida A, Kouchi M, Ishihara S, Tomiyama N, Kohagura K, Iseki K, Takishita S. Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient. Clin Nephrol. 2006; 66: 140-143.
20. Mataic D, Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail. 2006; 28: 361-363.
21. Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol. 2007; 143: 269-270.
22. Ackermann F, Levy A, Daugas E, Schartz N, Riaux A, Derancourt C, Urena P, Lebbe C. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol. 2007; 143: 1336-1337; author reply 1338.
23. Subramaniam K, Wallace H, Sinniah R, Saker B. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulfate. Australas J Dermatol. 2008; 49: 30-34.
24. Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial. 2010; 23: 258-262.
25. Price FM, Levick JR, Mason RM. Glycosaminoglycan concentration in synovium and other tissues of rabbit knee in relation to synovial hydraulic resistance. J Physiol. 1996; 495: 803-820.
26. Raymond CB, Wazny LD, Sood AR. Sodium thiosulfate, bisphosphonates, and cinacalcet for calciphylaxis. CANNTJ. 2009; 19: 25-27; quiz 28-29.
27. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol. 1985; 23: 63-67.
28. Asplin JR, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA. Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol. 2009; 20: 1246-1253.
29. Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int. 2008; 74: 1444-1453.
30. Adirekkiat S, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, PhakdeekitcharoenB, Kantachuvesiri S, Kitiyakara C, Klyprayong P, Disthabanchong S. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant. 2010; 25: 1923-1929.
31. O'Neill WC. Treatment of vascular calcification. Kidney Int. 2008; 74: 1376-1378.
32. Farah M, Crawford RI, Levin A, Chan Yan C. Calciphylaxis in the current era: emerging 'ironic' features? Nephrol Dial Transplant. 2010 (epub July 12).
33. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol. 2005; 4: 4.
34. Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009; 5: 539-543.